



Amarnath Kamath & Associates Chartered Accountants

INDEPENDENT AUDITORS' REPORT

To
The Members of Fagris Medica Private Limited,
Mumbai.

Report on the Standalone Financial Statements

We have audited the accompanying standalone financial statements of "Fagris Medica Private Limited" (the company), which comprise the Balance Sheet as at 31st March 2018, The Statement of Profit & Loss including Other Comprehensive Income, Cash Flow Statement and the Statement of Changes in Equity for the year then ended and a summary of significant accounting policies and other explanatory information ("hereinafter referred to as Standalone Financial Statement").

Managements Responsibility for Standalone Financial Statements

The Board of Directors of the company are responsible for preparation and presentation of Standalone Financial Statements according to Section 129 of the Companies Act 2013 (the act), which requires that the Financial Statements which give a true and fair view of the affairs of the company, comply with the Accounting Standards notified u/s 133 and in form and content be in accordance to Schedule III of the Act.

The above responsibility also includes apart from those matters included in section 134(5) of the act, maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

'CAREWEL HOUSE', Muniswamappa Layout, 6th Cross, Bangalore 560 017.
Landmark: Opp. TOTAL Mall, Off HAL Airport Road,
Phone: 91 80 25264700 Fax: 91 80 25264720





Amarnath Kamath & Associates Chartered Accountants

Auditors Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit. We have taken into account the provisions of the Act, the Accounting and Auditing Standards and matters which are required to be included in the Audit Report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An Audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls.

An Audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the Audit Evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.





Amarnath Kamath & Associates Chartered Accountants

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2018 and its Loss and its Cash Flows for the year ended on that date.

Report on other Legal and Regulatory Requirements

1) The Stand Alone Financial Statements of the Company attract the requirements of Companies (Auditor's Report) Order 2016 (the order) issued by the Central Government of India /us 143(11) of the Act. We have reported on the same in the Annexure - A to this report.

2) As required by Section 143 (3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c) The company has centralized accounting system and has no branch accounting. Therefore the process of reporting under sub-section (8) is not applicable.
- d) The balance sheet, the statement of profit and loss and the cash flow statement dealt with by this Report are in agreement with the books of account;
- e) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
- f) There are no such financial transactions or matters which have an adverse effect on the functioning of the company





Amarnath Kamath & Associates Chartered Accountants

- g) Based on Information & Explanation given to us and our Examination of the records and the information received from the Directors, none of the directors is disqualified as on 31st March, 2018 from being appointed as a director in terms of Section 164 (2) of the Act; and
- h) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- The Company has no Pending Litigation.
 - The Company has no Long Term Contracts or Derivatives, and hence it is not required to make any provision for loses under the Act or the Accounting Standards.
 - The Company is not required to transfer any funds to Investors Education and Protection Fund.
- i) The company has adequate internal financial control system in place and it is operating effectively. The same has been given in Annexure - B to this report

For Amarnath Kamath & Associates,
Chartered Accountants,
FRN 000099S

V. Narayanan



V Narayanan

Mem No. 219265

Place : Bangalore

Date : May 10th, 2018



Amarnath Kamath & Associates Chartered Accountants

Annexure -A to the Independent Auditors' Report

I. Fixed Assets

Based on the information provided to us and the verification conducted by us we opine that as the company does not hold any Movable or Immovable Assets, reporting under Companies Auditors Report Order, 2016 Clause 3(i) does not arise.

II. Inventory

Based on the information provided to us and the verification conducted by us we opine that as the company does not own any inventory or stock, reporting under clause 3(ii) of Companies Auditors' Report Order 2016 does not arise.

III. Loans, Borrowings & Guarantees - Granted

Based on the information provided to us and the verification conducted by us we opine that

- a) The company has not granted any loans, secured or unsecured to any of it's Directors, companies, firms, Limited Liability Partnership or other parties covered in the register maintained under section 189 of the Act.
- b) The company has not given any guarantee for loans taken by it's Directors or any other persons from Banks or Financial Institutions.

IV. Loans, Borrowings & Guarantees - Obtained

Based on the information provided to us and the verification conducted by us we opine that

- a. The Company has not obtained any Loan from Bank or Financial Institution. It does not have outstanding Debentures. Hence the question of reporting about defaults in repayment does not arise.

V. Public Deposits

Based on the information provided to us and the verification conducted by us we opine that the company has not accepted deposits under sections 73 to 76 of the Act during the period.





Amarnath Kamath & Associates Chartered Accountants

VI. Costing Records

Based on the information provided to us The Maintenance of Cost Records under section 148(1) of the act is not prescribed for the company.

VII. Statutory Matters

- a) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company is regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income Tax, Sales Tax, Wealth Tax, Service Tax, Duty of Customs, Duty of Excise, Value Added Tax, Cess and other statutory dues with appropriate authorities.
- b) According to the information and explanations given to us and on the basis of our examination of the records of the company, there are no instances of the company not depositing dues of any Taxes, Duties, Cess or other amounts due to disputes or other reason.
- c) The company has not declared any dividend since its incorporation. So there is no question in transferring of unclaimed dividend to Investors Education and Protection Fund in accordance with Companies Act 2013 and rules made there under.

VIII. Frauds

Based on the information provided to us and the verification conducted by us we opine that there is no instances of any Fraud or suspected fraud on or by the company is noticed or reported during the period

IX. Nidhi & NBFC Companies

The company is not a Nidhi Company nor is legally required to register under Section 45-IA of Reserve Bank of india Act. Therefore, commenting on clause 3(xii) and 3(xvi) of CARO, 2016 does not arise.

X. Issue of Shares

The company has not issued any shares during the year. Therefore, commenting under Clause 3(ix) and Clause 3(xiv) of CARO 2016 does not arise.

'CAREWEL HOUSE', Muniswamappa Layout, 6th Cross, Bangalore 560 017.
Landmark: Opp. TOTAL Mall, Off HAL Airport Road,
Phone: 91 80 25264700 Fax: 91 80 25264720





Amarnath Kamath & Associates Chartered Accountants

XI. Managerial Remuneration

No directors have been paid any remuneration during the year and hence Rule 3(xi) of CARO 2016 does not arise.

XII. Related Party Transactions

- a) The company has complied with section 188 requirements of the Act with regards to contracts, arrangements, and agreements etc., with its related parties. The necessary disclosure as per AS -18 i.e., Related Party Disclosures has been made in the notes to the Financial Statements.
- b) The company has not transacted with its directors. Hence reporting under Rule 3(xv) of CARO 2016 does not arise.

XIII. Non Cash Transaction with Directors

The company has not done any non cash transactions with the Directors or persons with whom Directors are interested during the year and hence reporting under clause 3(xv) does not arise.

For Amarnath Kamath & Associates,
Chartered Accountants,
FRN 000099S

V. Narayanan

V Narayanan

Mem No. 219265

Place: Bangalore

Date: May 10th, 2018





Amarnath Kamath & Associates Chartered Accountants

ANNEXURE- B TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF FAGRIS MEDICA PRIVATE LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of FAGRIS MEDICA PRIVATE LIMITED, ("the Company") as of March 31, 2018 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI. We have also carried out the responsibilities prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls.





Amarnath Kamath & Associates Chartered Accountants

Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness by obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
3. Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.





Amarnath Kamath & Associates

Chartered Accountants

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2016; based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.”.

For Amarnath Kamath & Associates,
Chartered Accountants,
FRN 0000995

V. Narayan

V Narayanan

Mem No. 219265

Place: Bangalore

+Date: May 10th, 2018




FAGRIS MEDICA PRIVATE LIMITED
BALANCE SHEET AS AT MARCH 31, 2018

	Note No.	Amount in INR	
		31-Mar-18	31-Mar-17
A ASSETS			
I Current assets			
(a) Financial assets			
(i) Trade receivables	1	9,897,763	-
(ii) Cash and cash equivalents	2	1,267,695	1,366,238
(iii) Other financial assets	3	240,232	-
(b) Other current assets	4	5,213,043	2,536,495
Total current assets		16,618,733	3,902,733
TOTA ASSETS		16,618,733	3,902,733
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	5	10,400,000	10,400,000
(b) Other equity	6	(9,410,025)	(9,468,147)
Total equity		989,975	931,853
II Liabilities			
1 Non-current liabilities			
(a) Provisions	7	-	75,091
		-	75,091
2 Current liabilities			
(a) Financials liabilities			
(i) Trade payables	8	7,529,276	-
(ii) Other financial liabilities	9	8,059,360	2,605,843
(b) Provisions	10	-	56
(c) Current tax liabilities	11	40,122	289,890
		15,628,758	2,895,789
TOTAL EQUITY AND LIABILITIES		16,618,733	3,902,733

The accompanying notes are an integral part of the financial statements

As per our report of even date attached
For **Amarnath Kamath & Associates**
Chartered Accountants
Firm Registration No. 000099S


V Narayanan
Partner
Mem. No. : 219265

Place : Bengaluru
Date: May 10, 2018



For and on behalf of Board of Directors


Alexander A
Director
DIN: 02276597



Mohan Kumar Pillai
Director
DIN: 01682413

FAGRIS MEDICA PRIVATE LIMITED
STATEMENT OF PROFIT AND LOSS
FOR THE YEAR ENDED MARCH 31, 2018

	Note No.	Amount in INR	
		31-Mar-18	31-Mar-17
1 Revenue from operations	12	13,000,058	(19,932,680)
2 Other income	13	-	6,983,790
3 Total revenue (1+2)		13,000,058	(12,948,890)
4 Expenses			
(a) Cost of materials consumed	14	2,872,006	(5,485,947)
(b) Employee benefits expenses	15	345,527	1,131,949
(c) Finance costs	16	33,148	2,428,126
(d) Depreciation and amortisation expense		-	111,607
(e) Other expenses	17	9,710,687	17,044,421
Total		12,961,367	15,230,156
5 Profit before exceptional items and tax (3-4)		38,691	(28,179,046)
6 Exceptional items gain / (loss) (net)		-	-
7 Profit before tax (5+6)		38,691	(28,179,046)
8 Tax expense	18	-	275,000
9 Profit for the year (7-8)		38,691	(28,454,046)
10 Other comprehensive income			
A) (i) Items that will not be reclassified to profit or loss		19,431	(6,779)
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-
B) (i) Items that may be reclassified to profit or loss		-	-
(ii) Income tax relating to items that may be reclassified to profit or loss		-	-
Total other comprehensive income		19,431	(6,779)
11 Total comprehensive income for the period (9+10)		58,122	(28,460,825)
12 Earnings per share (of Rs. 10/- each)			
- Basic		0.04	(155.99)
- Diluted		0.04	(155.99)

The accompanying notes are an integral part of the financial statements

As per our report of even date attached
For **Amarnath Kamath & Associates**
Chartered Accountants
Firm Registration No. 0000998


V Narayanan
Partner
Mem. No.: 219265



For and on behalf of Board of Directors


Alexander A
Director
DIN: 02276597


Mohan Kumar Pillai
Director
DIN: 01682413

Place : Bengaluru
Date: May 10, 2018

FAGRIS MEDICA PRIVATE LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEARS ENDED MARCH 31, 2018 AND MARCH 31, 2017

A) Equity share capital

Particulars	Amount in INR
Balance as at March 31, 2017	10,400,000
Changes in equity share capital during the year	-
Balance as at March 31,2018	10,400,000

(B) Other equity

Particulars	Reserves and surplus		Items of other comprehensive income	Total
	Capital reserve	Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2017	29,266,229	(38,714,945)	(19,431)	(9,468,147)
Profit/(loss) for the year	-	38,691	-	38,691
Other comprehensive income for the year	-	-	19,431	19,431
Total comprehensive income	-	38,691	19,431	58,122
Balance as at March 31,2018	29,266,229	(38,676,254)	-	(9,410,025)

The accompanying notes are an integral part of the financial statements

As per our report of even date attached
 For **Amarnath Kamath & Associates**
 Chartered Accountants
 Firm Registration No. 000099S

For and on behalf of Board of Directors

V Narayanan
 Partner
 Mem. No.: 219265



Alexander A
 Director
 DIN: 02276597

Mohan Kumar Pillai
 Director
 DIN: 01682413

Place : Bengaluru
 Date: May 10, 2018

FAGRIS MEDICA PRIVATE LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED MARCH 31, 2018

Particulars	Amount in INR	
	For the year ended	
	31-Mar-18	31-Mar-17
A. Cash flow from operating activities		
Net Profit /(loss) after tax	38,691	(28,454,046)
Adjustments for:		
-Provision for tax	-	275,000
-Depreciation and amortisation	-	111,607
-Finance costs	-	2,380,691
-Provision for gratuity & leave encashment	-	42,506
-Net unrealised exchange (gain) / loss	(505,661)	-
	<u>(505,661)</u>	<u>2,809,804</u>
Operating profit / (loss) before working capital changes	<u>(466,970)</u>	<u>(25,644,242)</u>
Changes in working capital:		
(Increase)/decrease in inventories	-	4,065,726
(Increase)/decrease in trade and other receivables	(12,289,451)	47,968,369
Increase/(decrease) in trade and other payables	5,643,981	(36,730,873)
	<u>(6,645,470)</u>	<u>15,303,222</u>
Net change in working capital	<u>(7,112,440)</u>	<u>(10,341,020)</u>
Cash generated from operations	<u>(7,112,440)</u>	<u>(10,341,020)</u>
Net income tax (paid) / refunds	(249,768)	-
Net cash flow from / (used in) operating activities (A)	<u>(7,362,208)</u>	<u>(10,341,020)</u>
B. Cash flow from investing activities		
Proceed from sale of business	-	29,490,579
Net cash flow from / (used in) investing activities (B)	<u>-</u>	<u>29,490,579</u>
C. Cash flow from financing activities		
Advance from related parties	7,263,665	-
Proceeds from issue of share capital	-	9,400,000
Proceeds from short-term borrowings	-	(27,910,000)
Finance costs	-	(2,380,691)
	<u>7,263,665</u>	<u>(20,890,691)</u>
Net cash flow from / (used in) financing activities (C)	<u>(98,543)</u>	<u>(1,741,132)</u>
Net increase / (decrease) in cash and cash equivalents (A+B+C)	<u>1,366,238</u>	<u>3,107,370</u>
Cash and cash equivalents at the beginning of the year	1,366,238	3,107,370
Cash and cash equivalents at the end of the year	<u>1,267,695</u>	<u>1,366,238</u>
Reconciliation of cash and cash equivalents with the Balance Sheet:		
Cash and cash equivalents as per Balance Sheet (Refer Note 2)	1,267,695	1,366,238
Less: Bank balances not considered as Cash and cash equivalents as defined in Ind AS 7 statement of cash flow.	-	-
Net Cash and cash equivalents as defined in IND AS 7 statement of cash flows included in Note 2	<u>1,267,695</u>	<u>1,366,238</u>
Add: Current investments considered as part of Cash and cash equivalents as defined in Ind AS 7 statement of cash flows	-	-
Cash and cash equivalents at the end of the year *	<u>1,267,695</u>	<u>1,366,238</u>
* Comprises:		
(a) Cash on hand	3,574	17,370
(b) Balances with banks - in current accounts	1,264,121	1,348,868
(c) Balances with banks - in fixed deposits	-	-

The accompanying notes are an integral part of the financial statements

As per our report of even date attached
For **Amarnath Kamath & Associates**
Chartered Accountants
Firm Registration No. 000099S

For and on behalf of Board of Directors

V Narayanan
Partner
Mem. No. : 219265

Place : Bengaluru
Date : May 10, 2018



Alexander A
Alexander A
Director
DIN: 02276597

Mohan Kumar Pillai
Mohan Kumar Pillai
Director
DIN: 01682413

FAGRIS MEDICA PRIVATE LIMITED
Notes forming part of the financial statements

Note No.

1 Trade receivables		Amount in INR	
Particulars	31-Mar-18	31-Mar-17	
Unsecured			
Considered good	9,897,763	-	
Considered doubtful	-	-	
	9,897,763	-	
Less: allowance for doubtful trade receivables	-	-	
Total	9,897,763	-	
2 Cash and cash equivalents		Amount in INR	
Particulars	31-Mar-18	31-Mar-17	
Cash on hand	3,574	17,370	
Balance with banks:			
- In current account	1,264,121	1,348,868	
Total	1,267,695	1,366,238	
3 Other financial assets		Amount in INR	
Particulars	31-Mar-18	31-Mar-17	
Advances to related parties	240,232	-	
Total	240,232	-	
4 Other current assets		Amount in INR	
Particulars	31-Mar-18	31-Mar-17	
Balances with government authorities:			
- CENVAT credit receivable	-	942,709	
- VAT credit receivable	-	1,090,657	
- Incentives receivables	265,969	503,129	
- GST receivables	4,947,074	-	
Total	5,213,043	2,536,495	
5 Equity share capital		Amount in INR	
Particulars	31-Mar-18	31-Mar-17	
Authorised			
1,605,000 equity shares of Rs. 10/- each with voting rights (March 31, 2017)	16,050,000	16,050,000	
1,605,000 Equity shares of Rs. 10/-each			
6% 5,000 redeemable non cumulative preference shares of Rs.10/- each. (March 31, 2017)	50,000	50,000	
6% 5,000 redeemable non cumulative preference shares of Rs. 10/-each			
Total	16,100,000	16,100,000	
Issued, subscribed and fully paid-up			
1,040,000 equity shares of Rs.10/- each with voting rights (March)	10,400,000	10,400,000	
31,2017 1,040,000 Equity shares of Rs. 10/-each			
Total	10,400,000	10,400,000	

(a) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

Particulars	31-Mar-18		31-Mar-17	
	No. of Shares	Amount in INR	No. of Shares	Amount in INR
Equity share of Rs. 10/- each				
Opening balance	1,040,000	10,400,000	100,000	1,000,000
Issued during the year	-	-	940,000	9,400,000
Closing balance	1,040,000	10,400,000	1,040,000	10,400,000

(b) Detail of the rights, preferences and restrictions attaching to each class of shares outstanding equity shares of Rs. 10/- each:

The Company has only one class of equity shares, having a par value of Rs.10/-. The holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive any of the remaining assets of the Company, after distribution to all other parties concerned. The distribution will be in proportion to number of equity shares held by the shareholders.

(c) Details of equity shares held by each shareholder holding more than 5% of shares:

Particulars	31-Mar-18		31-Mar-17	
	No. of	% Of shares	No. of	% Of shares
Strides Shasun Limited	1,040,000	100%	1,040,000	100%
Total	1,040,000	100%	1,040,000	100%



FAGRIS MEDICA PRIVATE LIMITED
Notes forming part of the financial statements

Note
No.

6 Other equity	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Capital reserve		
Opening balance	29,266,229	29,266,229
Add : On transfer of business	-	-
Closing balance	29,266,229	29,266,229
Surplus in statement of profit and loss		
Opening balance	(38,714,945)	(10,260,899)
Add: Profit/(loss) for the year	38,691	(28,454,046)
Closing balance	(38,676,254)	(38,714,945)
Items of other comprehensive income		
Opening balance	(19,431)	(12,652)
Add/(Less) : other comprehensive income for the year	19,431	(6,779)
Add/(Less): Tax impact on above	-	-
Closing balance	-	(19,431)
Total	(9,410,025)	(9,468,147)
7 Non current provision	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Gratuity	-	75,091
Total	-	75,091
8 Trade payables	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Trade payables:		
- Total outstanding dues of micro enterprises and small enterprises	-	-
- Total outstanding dues of creditors other than micro and small enterprises	7,529,276	-
Total	7,529,276	-
9 Other financial liabilities	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Dues to related parties	7,280,556	16,891
Other payables:		
- Statutory remittances	778,804	2,588,952
Total	8,059,360	2,605,843
10 Current provision	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Gratuity	-	56
Total	-	56
11 Current tax liabilities	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Provision for income tax	40,122	289,890
Total	40,122	289,890



FAGRIS MEDICA PRIVATE LIMITED
Notes forming part of the financial statements

Note
No.

12 Revenue from operations	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Sale of products	12,351,279	(19,113,159)
Other operating revenues	648,779	(819,521)
Total	13,000,058	(19,932,680)

(i) Sale of products for the previous year ended March 31, 2017 include Rs.29,043,242/- towards return of goods sold during the year ended March 31, 2016.

(ii) Other operating revenues for the previous ended March 31, 2017 include Rs.1,247,115/- towards reversal and payment of government incentives claimed on the above sales return.

Note: Other operating revenue comprises:

Particulars	31-Mar-18	31-Mar-17
Government incentive	348,779	(819,521)
Support service income	300,000	-
Total	648,779	(819,521)

13 Other income	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Others	-	6,983,790
Total	-	6,983,790

(i) other income during the previous year includes claims received from transporters and insurance towards shipment damage.

14 Cost of materials consumed	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Opening stock	-	4,065,728
Add: Purchases	2,872,006	(9,551,675)
Add: Excise duty	-	1,465,394
Closing stock	-	-
Cost of materials consumed	2,872,006	(5,485,947)

(i) Purchases during the previous year ended March 31, 2017 includes return of goods purchased during the year ended March 31, 2016 on account of sales return as mentioned above.

15 Employee benefits expenses	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Salaries and wages	334,145	1,117,894
Staff welfare expenses	11,382	14,055
Total	345,527	1,131,949

16 Finance costs	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Interest expense on:		
- Borrowings	-	2,380,691
- Delayed payment of income tax	6,503	3,997
Other finance costs	26,645	43,438
Total	33,148	2,428,126



FAGRIS MEDICA PRIVATE LIMITED
Notes forming part of the financial statements

Note
No.

17 Other expenses	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Subcontracting	6,216	10,000
Rent	399,075	278,963
Power charges	13,175	-
Water charges	660	-
Repairs and maintenance:		
- Others	-	8,935
Insurance	-	20,150
Rates and taxes	1,436,007	313,107
Communication	70,425	63,355
Travelling and conveyance	61,194	819,443
Printing and stationery	13,687	14,974
Freight and forwarding	3,019,581	3,369,175
Business promotion	1,375,648	520
Legal and professional	336,608	2,606,077
Payments to auditors	200,000	50,000
Testing and analysis expenses	1,408,390	998,739
Support Service charges	226,125	906,183
Net loss on foreign currency transactions	198,781	364,868
Provision for doubtful trade receivables	-	7,200,029
Miscellaneous expenses	945,115	19,903
Total	9,710,687	17,044,421

(i) Payments to the statutory auditors of the company comprises (net of GST Credit) for:

		Amount in INR	
Particulars	31-Mar-18	31-Mar-17	
Statutory audit fee	200,000	50,000	
Tax audit fee	-	-	
For certification and others	-	-	
Total	200,000	50,000	

18 Tax expenses	Amount in INR	
Particulars	31-Mar-18	31-Mar-17
Current tax expenses	-	275,000
Total	-	275,000



Note 29**Related party disclosures**

Related party classification	Name of related party
Holding company	Strides Shasun Limited
Fellow subsidiary	Strides Pharma (Cyprus) Limited

Related party transactions during the year ended March 31, 2018

Nature of transactions	Holding company		Fellow subsidiary	
	Year ended 31-Mar-18	Year ended 31-Mar-17	Year ended 31-Mar-18	Year ended 31-Mar-17
a) Loans & advances - taken / repaid (net)	(3,734,720)	(27,910,000)	-	-
b) Sale of goods	-	3,587,821	1,789,111	-
c) Support service income	300,000	-	-	-
d) Support service charges	225,000	906,183	-	-
e) Reimbursement of expenses incurred by	3,781,206	741,308	-	-
f) Reimbursement of expenses incurred on behalf of	826,000	-	-	-
g) Interest expenses	-	2,380,690	-	-
h) Rental expenses	60,000	60,300	-	-
i) Issue of share capital	-	9,400,000	-	-
j) Consideration for sale of business	-	30,454,170	-	-

Related party balances as at March 31st, 2018

Nature of Transactions	Holding company		Fellow subsidiary	
	Year ended 31-Mar-18	Year ended 31-Mar-17	Year ended 31-Mar-18	Year ended 31-Mar-17
a) Loans & advances receivables /(payables)	(3,069,507)	16,891	235,935	-
b) Trade receivables	1,042,000	-	4,073,812	-
c) Trade payables	4,724,372	-	-	-

Note 30**Earnings per share**

Particulars	31-Mar-18	31-Mar-17
Net profit after tax (In INR)	38,691	(28,454,046)
Weighted average number of equity shares (No.s)	1,040,000	182,411
Earnings/(loss) per share (In INR)	0.04	(155.99)
Nominal value of equity shares (In INR)	10.00	10.00

Note 31**Foreign currency exposure**

Foreign currency exposure that have not been hedged by a derivative instrument or otherwise:

Particulars	31-Mar-18		31-Mar-17	
	Amount in USD	Amount in INR	Amount in USD	Amount in INR
Receivables	268,729	17,507,667	-	-
Total	268,729	17,507,667	-	-

Note 32

During the previous year 2016-17, the company entered into an agreement to sell its business to Strides Shasun Limited (holding company) on february 7, 2017. Pursuant to the above agreement the company entered into a transitional service agreement for providing the services of sales, distribution and marketing of products on behalf of its holding company. The assets and liabilities of the sold business from the aforesaid date is pertaining to the holding company and the profits/(loss), net of all costs and applicable taxes, arising out of the sold business would accrue to the holding company.

Note 33

Previous year figures have been regrouped and reclassified where necessary to conform to current year figures.

For and on behalf of Board of Directors



Place : Bengaluru
Date: May 10, 2018


Alexander A
Director
DIN: 02276597


Mohan Kumar Pillai
Director
DIN: 01682413

FAGRIS MEDICA PRIVATE LIMITED

NOTES ON FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31st MARCH 2018

Note No.-34

COMPANY INFORMATION

Fagris Medica Private Limited is a pharmaceutical company having corporate office in Bengaluru, India. The company is engaged in business of manufacturing, marketing and commercializing of OTC products in CIS countries.

Note No.-35

SIGNIFICANT ACCOUNTING POLICIES:

A. Basis for preparation of Financial statements

The Company is a wholly owned subsidiary of Strides Shasun Limited, a listed company which is required to prepare its financial statements in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. Accordingly, these financial statements are also prepared in accordance with Ind AS under the historical cost convention on the accrual basis with revenues recognized and expenses accounted on their accrual, including provisions / adjustments for committed obligations and amounts determined as payable or receivable during the year.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

B. Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

C. Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities are segregated based on the available information.



D. Revenue recognition

- (a) **Sale of goods:** Sales are recognised, net of returns and trade discounts, on transfer of significant risks and rewards of ownership to the buyer as per the terms of the arrangements with buyer.
- (b) **Export incentives** are accrued for based on fulfillment of eligibility criteria for availing the incentives and when there is no uncertainty in receiving the same. These incentives include estimated realisable values/benefits from special import licenses and benefits under Duty Entitlement Pass Book Schemes, Focus Market Schemes, and Market-Linked Focus scheme.
- (c) **Other income**
Support service income is accounted on accrual basis.

E. Foreign currency transactions and translations

Transactions denominated in Foreign Currencies are recorded using the exchange rates prevailing on the date of transaction. The difference if any, on actual payment/ realization is charged off to revenue. Amount receivable / payable as at the close of the year is accounted at the prevailing rates and the difference if any, on receipt / while making actual payment due to fluctuation in the rate of exchange is charged to revenue in that year

F. Leases

Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vests with the lessor are recognized as operating leases. Lease rentals under operating leases are recognized in the Statement of Profit and Loss on a straight-line basis over the lease term.

G. Earnings Per Share

Earnings per share is computed by dividing the profit / (loss) after tax by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax as adjusted for dividend, interest and other charges to expense or income relating to dilutive potential equity shares, by the weighted average number of equity shares considered for deriving the basic earnings per share and also the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share and are deemed to be converted at the beginning of the period, unless they have been issued later.

H. Taxes on income

The current charge for income tax (if any) is calculated in accordance with the relevant tax regulations applicable to the Company.

Minimum alternate tax paid (if any) in accordance with the tax laws, which gives future economic benefits adjustments to the future income tax liability is considered an asset if there is convincing evidence that the Company will pay normal tax in future.



Deferred tax assets and liabilities (if any) are recognized for future tax consequences attributable to the timing differences that result between the profit offered for income tax and the profit as per financial statements. Deferred tax assets and liabilities are measured as per the tax rates / laws that have been enacted or substantively enacted by the Balance Sheet Date.

I. Provisions and contingencies

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are disclosed in the Notes. Contingent assets are not recognised in the financial statements.

Place: Bengaluru
Date: May 10, 2018

For and on behalf of the Board


Alexander A
Director
DIN: 02276597


Mohan Kumar Pillai
Director
DIN: 01682413

